Author

Tamás Molnár

EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSE BOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATE WITH SODIUM PICOSULFATE IN SPECIAL GROUPS OF PATIENTS
EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSE BOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATE WITH SODIUM PICOSULFATE IN SPECIAL GROUPS OF PATIENTS

Tamás Molnár  et al.

EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY

Tamás Molnár  et al.

EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSE BOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATE WITH SODIUM PICOSULFATE IN SPECIAL GROUPS OF PATIENTS
EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSE BOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATE WITH SODIUM PICOSULFATE IN SPECIAL GROUPS OF PATIENTS

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Tamás Molnár  et al.

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY
CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Tamás Molnár  et al.

INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 PANDEMIC - THE PATIENT'S PERSPECTIVE
INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 PANDEMIC - THE PATIENT'S PERSPECTIVE

Tamás Molnár  et al.

HEAVY PSEUDOPOLYP BURDEN IN INFLAMMATORY BOWEL DISEASE PREDICTS MORE SEVERE DISEASE: A MULTICENTRE COHORT STUDY
HEAVY PSEUDOPOLYP BURDEN IN INFLAMMATORY BOWEL DISEASE PREDICTS MORE SEVERE DISEASE: A MULTICENTRE COHORT STUDY

Tamás Molnár  et al.

CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS
CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOIDS FROM INFLAMMATORY BOWEL DISEASE PATIENTS

Tamás Molnár  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Tamás Molnár  et al.

QUALITY INDICATORS AND RESULTS OF COLONOSCOPY EXAMINATIONS IN THE FIRST YEAR OF HUNGARIAN POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM - A NATIONWIDE COHORT STUDY
QUALITY INDICATORS AND RESULTS OF COLONOSCOPY EXAMINATIONS IN THE FIRST YEAR OF HUNGARIAN POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM - A NATIONWIDE COHORT STUDY

Tamás Molnár  et al.

NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Tamás Molnár  et al.

CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE
CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE

Tamás Molnár  et al.

INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE
INCREASED EXPRESSION OF SERPIN E1, A POTENTIAL NEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITY AND THERAPEUTIC NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE

Tamás Molnár  et al.

FIRST-YEAR ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS
FIRST-YEAR ADHERENCE TO THE HUNGARIAN POPULATION-BASED COLORECTAL SCREENING PROGRAM AND POTENTIAL INFLUENCING DEMOGRAPHIC FACTORS

Tamás Molnár  et al.

POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES
POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES

Tamás Molnár  et al.

COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS
COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS

Tamás Molnár  et al.

THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE
THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE

Tamás Molnár  et al.

LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL
LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL

Tamás Molnár  et al.

COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS
COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS

Tamás Molnár  et al.

MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE
MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE

Tamás Molnár  et al.

Item 1 - 20 / 32
1
2